ADMA Biologics saw its IBD SmartSelect Composite Rating rise to 96 Monday, up from 94 the day before.
Looking For The Best Stocks To Buy And Watch? Start Here
The upgrade means the stock is now outperforming 96% of all other stocks in terms of key performance metrics and technical strength. History shows the top market performers tend to have a 95 or higher score as they launch their major moves.
ADMA Biologics is not currently near a proper buy zone. See if the stock goes on to form a new chart pattern and offer a new buying opportunity.
The stock has an 80 EPS Rating, meaning its recent quarterly and longer-term annual earnings growth is outpacing 80% of all stocks.
Its Accumulation/Distribution Rating of C shows a roughly equal amount of buying and selling by institutional investors over the last 13 weeks.
The company posted a 75% rise in earnings for Q1. Top line growth fell to 40%, down from 59% in the prior quarter.
ADMA Biologics holds the No. 3 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis is the top-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
